These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31730163)

  • 41. Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
    Shi S; Zhang X; Yao Z; Xu M; Zhou B; Liu Q; Zhang Y; Zhou C; Zhou T; Ye J
    J Antimicrob Chemother; 2022 Apr; 77(5):1301-1305. PubMed ID: 35165715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibacterial activity and carbapenem re-sensitizing ability of 1,10-phenanthroline-5,6-dione and its metal complexes against KPC-producing Klebsiella pneumoniae clinical strains.
    Vianez Peregrino I; Ferreira Ventura R; Borghi M; Pinto Schuenck R; Devereux M; McCann M; Souza Dos Santos AL; FerreiraNunes AP
    Lett Appl Microbiol; 2021 Aug; 73(2):139-148. PubMed ID: 33843058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
    Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibiofilm peptides increase the susceptibility of carbapenemase-producing Klebsiella pneumoniae clinical isolates to β-lactam antibiotics.
    Ribeiro SM; de la Fuente-Núñez C; Baquir B; Faria-Junior C; Franco OL; Hancock RE
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3906-12. PubMed ID: 25896694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.
    Brennan-Krohn T; Truelson KA; Smith KP; Kirby JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2775-2781. PubMed ID: 29091221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae.
    DeSarno AE; Parcell BJ; Coote PJ
    Pathog Dis; 2020 Dec; 78(9):. PubMed ID: 33053176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of parenteral Beta-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum Beta-lactamase producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Int J Antimicrob Agents; 2004 Jul; 24(1):48-52. PubMed ID: 15225861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro.
    Zhang J; Yu L; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Li C; Zhang X
    Ann Palliat Med; 2019 Nov; 8(5):622-631. PubMed ID: 31735038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae.
    Fredborg M; Sondergaard TE; Wang M
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):355-360. PubMed ID: 28583381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis.
    Tattevin P; Dinh A; Ghout I; Mouton W; Verdier MC; Laurent F; Lemaitre F; Gatin L; Saleh-Mghir A; Crémieux AC
    Int J Antimicrob Agents; 2020 Nov; 56(5):106152. PubMed ID: 32898684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN) increases resistance to carbapenems in Chilean clinical isolates of KPC-producing Klebsiella pneumoniae.
    Vera-Leiva A; Carrasco-Anabalón S; Lima CA; Villagra N; Domínguez M; Bello-Toledo H; González-Rocha G
    J Glob Antimicrob Resist; 2018 Mar; 12():73-76. PubMed ID: 29275225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Bowker KE; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.
    Yigit H; Queenan AM; Anderson GJ; Domenech-Sanchez A; Biddle JW; Steward CD; Alberti S; Bush K; Tenover FC
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1151-61. PubMed ID: 11257029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.
    Sharma R; Patel S; Abboud C; Diep J; Ly NS; Pogue JM; Kaye KS; Li J; Rao GG
    Int J Antimicrob Agents; 2017 Feb; 49(2):224-232. PubMed ID: 28040408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.